RetinalGenix Technologies Agrees To Hire M. Cory Zwerling as CFO, Interim COO

Core Insights - RetinalGenix Technologies Inc. has appointed M. Cory Zwerling as chief financial officer and interim chief operating officer, effective January 1, 2026, to guide the company through its commercial launch [1][2] Group 1: Leadership and Experience - Mr. Zwerling brings over 30 years of experience in healthcare, finance, and operations, particularly in pharmaceuticals, medical imaging, biotechnology, and digital health [1][2] - His background includes leadership roles in global pharmaceutical and imaging divisions, founding a healthcare IT/AI company, and serving as CEO of a medical-device venture, aligning with RetinalGenix's transition from R&D to commercial operations [3] Group 2: Company Strategy and Technology - RetinalGenix is focused on revolutionizing early disease detection and improving patient outcomes through the integration of genetic screening, advanced imaging, and therapeutic development [4] - The company is developing proprietary technologies aimed at preventing blindness and detecting physiological changes indicative of various diseases, including neurodegenerative and cardiovascular conditions [4]